Stock LAURUSLABS LAURUS LABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Laurus Labs Limited

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:42:30 2024-04-30 am EDT 		5-day change 1st Jan Change
450 INR +1.41% Intraday chart for Laurus Labs Limited +4.64% +4.60%
Apr. 25 Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024
Apr. 25 Laurus Labs' Consolidated Profit Falls in Fiscal Q4 MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 42,527 34,726 194,250 317,096 157,798 242,535 - -
Enterprise Value (EV) 1 51,926 44,264 208,321 333,657 177,033 211,463 264,889 264,629
P/E ratio 45.4 x 13.6 x 19.8 x 38.4 x 20 x 132 x 56.2 x 34.8 x
Yield 0.38% 0.77% 0.55% 0.34% 0.68% 0.29% 0.33% 0.39%
Capitalization / Revenue 1.86 x 1.23 x 4.04 x 6.42 x 2.61 x 4.2 x 4.11 x 3.55 x
EV / Revenue 2.27 x 1.56 x 4.33 x 6.76 x 2.93 x 4.2 x 4.49 x 3.88 x
EV / EBITDA 14.6 x 7.84 x 13.4 x 23.5 x 11.1 x 27.2 x 23.1 x 17 x
EV / FCF 120 x 35.3 x 424 x 974 x 4,733 x 98.2 x 108 x 111 x
FCF Yield 0.84% 2.83% 0.24% 0.1% 0.02% 1.02% 0.93% 0.9%
Price to Book 2.73 x 1.96 x 15 x 9.49 x 3.91 x 5.76 x 5.34 x 4.68 x
Nbr of stocks (in thousands) 532,184 534,572 536,602 537,359 538,651 538,966 - -
Reference price 2 79.91 64.96 362.0 590.1 293.0 450.0 450.0 450.0
Announcement Date 5/2/19 4/30/20 4/29/21 4/28/22 4/27/23 4/25/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,919 28,317 48,135 49,356 60,406 50,408 58,957 68,277
EBITDA 1 3,560 5,645 15,507 14,224 15,922 7,775 11,480 15,567
EBIT 1 1,918 3,773 13,456 11,709 12,681 3,929 7,374 11,007
Operating Margin 8.37% 13.32% 27.95% 23.72% 20.99% 7.79% 12.51% 16.12%
Earnings before Tax (EBT) 1 1,198 2,936 13,011 10,838 11,089 2,364 6,192 9,922
Net income 1 937.6 2,553 9,836 8,275 7,901 1,606 4,430 7,303
Net margin 4.09% 9.01% 20.43% 16.77% 13.08% 3.18% 7.51% 10.7%
EPS 2 1.760 4.786 18.28 15.35 14.64 2.970 8.007 12.93
Free Cash Flow 1 434 1,254 491.2 342.6 37.4 2,656 2,460 2,388
FCF margin 1.89% 4.43% 1.02% 0.69% 0.06% 5.25% 4.17% 3.5%
FCF Conversion (EBITDA) 12.19% 22.21% 3.17% 2.41% 0.23% 32.74% 21.43% 15.34%
FCF Conversion (Net income) 46.29% 49.12% 4.99% 4.14% 0.47% 136.31% 55.55% 32.7%
Dividend per Share 2 0.3000 0.5000 2.000 2.000 2.000 1.320 1.467 1.767
Announcement Date 5/2/19 4/30/20 4/29/21 4/28/22 4/27/23 4/25/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 12,884 14,119 12,785 12,035 10,288 14,248 15,389 15,759 15,448 13,809 11,818 13,633 13,597 14,331 13,502
EBITDA 1 4,263 4,722 3,954 3,479 2,853 3,967 4,542 4,489 4,036 2,855 1,667 2,650 2,648 2,690 -
EBIT 1 3,747 4,186 3,368 2,819 2,213 3,310 3,834 3,671 3,191 1,985 761.7 1,888 2,082 1,922 1,418
Operating Margin 29.08% 29.64% 26.34% 23.42% 21.51% 23.23% 24.91% 23.29% 20.66% 14.38% 6.45% 13.85% 15.31% 13.41% 10.5%
Earnings before Tax (EBT) 1 3,642 4,012 3,160 2,626 2,035 3,017 3,559 3,281 2,778 1,471 405.8 1,567 1,710 1,307 -
Net income 1 2,728 2,967 2,414 2,019 1,550 2,305 2,513 2,328 2,030 1,030 248.5 1,055 1,016 883.6 -
Net margin 21.18% 21.01% 18.88% 16.78% 15.06% 16.18% 16.33% 14.77% 13.14% 7.46% 2.1% 7.74% 7.47% 6.17% -
EPS 2 5.070 5.500 4.480 3.740 2.850 4.280 4.660 4.320 3.760 1.900 0.4600 2.600 2.000 1.400 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/28/21 4/29/21 7/29/21 10/28/21 1/27/22 4/28/22 7/27/22 10/21/22 1/30/23 4/27/23 7/27/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 9,400 9,538 14,071 16,561 19,235 18,407 22,355 22,094
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.64 x 1.69 x 0.9074 x 1.164 x 1.208 x 2.269 x 1.947 x 1.419 x
Free Cash Flow 1 434 1,254 491 343 37.4 2,656 2,461 2,388
ROE (net income / shareholders' equity) 6.17% 15.3% 45% 27.8% 21.4% 5% 10.8% 14.8%
ROA (Net income/ Total Assets) - - - 13% 10.8% 2% 5% 8%
Assets 1 - - - 63,594 73,142 97,441 88,593 91,286
Book Value Per Share 2 29.30 33.10 24.20 62.20 75.00 78.20 84.30 96.20
Cash Flow per Share - - - - - - - -
Capex 1 2,538 2,220 6,839 8,768 9,902 9,160 7,067 6,696
Capex / Sales 11.07% 7.84% 14.21% 17.77% 16.39% 18.11% 11.99% 9.81%
Announcement Date 5/2/19 4/30/20 4/29/21 4/28/22 4/27/23 4/25/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Laurus Labs Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
450 INR
Average target price
383.4 INR
Spread / Average Target
-14.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LAURUS LABS LIMITED Stock Laurus Labs Limited
+4.60% 2.87B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
AMGEN INC. Stock Amgen Inc.
-4.89% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAURUSLABS Stock
  4. Financials Laurus Labs Limited